KRAS and colorectal carcinoma: By comparing the genomic alteration of 20q13.33 gain with APC and KRAS mutations (62.63% vs 42.93 and 23.73%, respectively), which are currently identified as the most important targets for CRC therapy [33], the results support that 20q13.33 gain may have been involved in the development of cancer.